Compare JAZZ & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | TECH |
|---|---|---|
| Founded | 2003 | 1976 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.6B |
| IPO Year | 2007 | 1995 |
| Metric | JAZZ | TECH |
|---|---|---|
| Price | $202.48 | $54.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $217.57 | $71.82 |
| AVG Volume (30 Days) | 832.5K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | ★ $1,618,693,000.00 | $1,219,635,000.00 |
| Revenue This Year | $6.22 | $2.49 |
| Revenue Next Year | $7.68 | $6.40 |
| P/E Ratio | ★ N/A | $113.32 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $105.00 | $46.05 |
| 52 Week High | $207.48 | $72.16 |
| Indicator | JAZZ | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 48.68 |
| Support Level | $194.77 | $49.55 |
| Resistance Level | $207.48 | $58.88 |
| Average True Range (ATR) | 5.09 | 2.71 |
| MACD | -0.29 | -0.35 |
| Stochastic Oscillator | 60.62 | 33.57 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.